View Older Stories View More Recent Stories
-
AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 3% Yield
-
Cantor Fitzgerald Reiterates Overweight Rating on Abbvie (ABBV)
-
Bernstein: 'We Anticipate Abbvie (ABBV) To Be Down MSD Today'
-
Abbvie (ABBV) PT Lowered to $228 at Evercore ISI
-
AbbVie (ABBV) executive: Abbvie: peak sales for Parkinson's and migraine franchises could exceed $5 billion
-
AbbVie beats Q4 expectations, shares dip
-
AbbVie (ABBV) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
-
AbbVie earnings preview: Bernstein expects another tightly framed outlook
-
AbbVie submits vitiligo treatment application to FDA and EMA
-
AbbVie (ABBV) call put ratio 2.3 calls to 1 put into quarter results
-
Goldman Sachs Reiterates Neutral Rating on Abbvie (ABBV) Ahead of Earnings
-
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Bernstein Reiterates Market Perform Rating on Abbvie (ABBV)
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)
-
UBS Reiterates Neutral Rating on Abbvie (ABBV)
-
AbbVie (ABBV) and Trump Administration Reach Agreement To Cut Drug Prices, $100 bln Investment
-
AbbVie licenses cancer drug from RemeGen for $650 million upfront
-
HSBC lists 11 potential U.S. outperformers heading into earnings
-
Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
-
AbbVie (ABBV) call put ratio 1.3 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked in - Wolfe
-
Wolfe Research Downgrades Abbvie (ABBV) to Peerperform
-
After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more
-
Abbvie: Not In Discussions With Revolution Medicines - Reuters
-
AbbVie reports $1.3 billion Q4 expense from acquired research deals
-
AbbVie in Advanced Talks to Buy Revolution Medicines - WSJ
-
UBS Assumes Abbvie (ABBV) at Neutral
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Trump to announce prescription drug price agreements
-
HSBC highlights one pharma stock to buy and one to sell for 2026
-
HSBC Upgrades Abbvie (ABBV) to Buy
-
AbbVie's SKYRIZI receives positive reimbursement nod in Canada for UC
-
Bernstein on IRA pricing: $245 really is the floor
-
FDA issues warning letters to 18 websites selling unapproved Botox products
-
Abbvie (ABBV) PT Raised to $225 at Bernstein SocGen Group
-
DZ Bank Downgrades Abbvie (ABBV) to Hold
-
Abbvie (ABBV) PT Raised to $256 at Raymond James
-
AbbVie (ABBV) Tops Q3 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
-
Analysts expect AbbVie’s core franchises to offset R&D costs ahead of Q3 earnings
-
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
-
AbbVie (ABBV) call put ratio 1.8 calls to 1 put into quarter results
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Abbvie (ABBV) PT Raised to $258 at BMO Capital
-
AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
-
Abbvie (ABBV) PT Raised to $242 at Guggenheim, 'Looking for Additional Treats on Halloween to Drive Further Upside'
-
Abbvie (ABBV) PT Raised to $250 at Raymond James
-
Cantor Fitzgerald Notes IPR&D Charge Impact on Abbvie's (ABBV) 3Q EPS
-
Erste Group Downgrades Abbvie (ABBV) to Hold
-
FDA approves expanded RINVOQ indication for inflammatory bowel disease
